NeoGenomics (NASDAQ:NEO – Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.080-0.100 for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $661.7 million.
NeoGenomics Stock Up 3.5 %
Shares of NASDAQ NEO traded up $0.53 during midday trading on Wednesday, hitting $15.46. The company’s stock had a trading volume of 1,244,304 shares, compared to its average volume of 770,070. The business’s fifty day simple moving average is $14.71 and its two-hundred day simple moving average is $14.73. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. NeoGenomics has a 1 year low of $12.77 and a 1 year high of $21.22. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -24.94 and a beta of 1.19.
Analysts Set New Price Targets
NEO has been the subject of several recent research reports. Benchmark reissued a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Wednesday. Finally, Stephens reiterated an “overweight” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Tuesday, July 30th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, NeoGenomics has a consensus rating of “Moderate Buy” and a consensus target price of $19.89.
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Read More
- Five stocks we like better than NeoGenomics
- What Are Dividends? Buy the Best Dividend Stocks
- What a Trump Win Looks Like for the Market Now and Into 2025
- Why Are These Companies Considered Blue Chips?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What Are Dividend Challengers?
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
